Fig. 4From: Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in ChinaCost-effectiveness acceptability curves at different thresholds of willingness to pay ABE + ET: abemaciclib + endocrine therapy; ET: endocrine therapyBack to article page